CN107698795A - A kind of porous polymer microsphere preparation method and applications of structure-controllable - Google Patents
A kind of porous polymer microsphere preparation method and applications of structure-controllable Download PDFInfo
- Publication number
- CN107698795A CN107698795A CN201710916206.2A CN201710916206A CN107698795A CN 107698795 A CN107698795 A CN 107698795A CN 201710916206 A CN201710916206 A CN 201710916206A CN 107698795 A CN107698795 A CN 107698795A
- Authority
- CN
- China
- Prior art keywords
- water
- solution
- porous polymer
- emulsion
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/28—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/622—Microcapsules
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2201/00—Foams characterised by the foaming process
- C08J2201/04—Foams characterised by the foaming process characterised by the elimination of a liquid or solid component, e.g. precipitation, leaching out, evaporation
- C08J2201/048—Elimination of a frozen liquid phase
- C08J2201/0482—Elimination of a frozen liquid phase the liquid phase being organic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2201/00—Foams characterised by the foaming process
- C08J2201/04—Foams characterised by the foaming process characterised by the elimination of a liquid or solid component, e.g. precipitation, leaching out, evaporation
- C08J2201/048—Elimination of a frozen liquid phase
- C08J2201/0484—Elimination of a frozen liquid phase the liquid phase being aqueous
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2329/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal, or ketal radical; Hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Derivatives of such polymer
- C08J2329/02—Homopolymers or copolymers of unsaturated alcohols
- C08J2329/04—Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2405/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
- C08J2405/16—Cyclodextrin; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2467/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
- C08J2467/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2471/00—Characterised by the use of polyethers obtained by reactions forming an ether link in the main chain; Derivatives of such polymers
- C08J2471/02—Polyalkylene oxides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
Abstract
一种结构可控的多孔聚合物微球制备方法及其应用,将环糊精溶液与聚乙二醇溶液混合后,加入到PLGA的二氯甲烷溶液中,超声得到水/油乳化液,将水/油乳化液加入到PVA溶液中,超声得到水/油/水乳化液,将水/油/水乳化液在室温下搅拌后,水洗,冷冻干燥得到多孔聚合物微球。通过控制乳化液熟化时间,仅用一步反应就制备出了具有不同孔结构的多孔聚合物微球,制备方法简单,易于实现工业化生产。本发明反应周期短,产率高,能有效提高工作效率。该多孔聚合物微球能够应用在制备用于修复皮肤的凝胶贴片中,对于皮肤修复有较好的效果。A method for preparing porous polymer microspheres with controllable structure and its application. After mixing the cyclodextrin solution and the polyethylene glycol solution, add it to the dichloromethane solution of PLGA, and obtain the water/oil emulsion by ultrasonication. The water/oil emulsion is added to the PVA solution, and the water/oil/water emulsion is obtained by ultrasonication. The water/oil/water emulsion is stirred at room temperature, washed with water, and freeze-dried to obtain porous polymer microspheres. By controlling the aging time of the emulsion, the porous polymer microspheres with different pore structures are prepared by only one-step reaction, the preparation method is simple, and the industrial production is easy to realize. The invention has short reaction cycle, high yield and can effectively improve working efficiency. The porous polymer microsphere can be applied in the preparation of a gel patch for repairing the skin, and has a good effect on skin repairing.
Description
技术领域technical field
本发明涉及高分子材料技术与生物医用材料领域,具体涉及一种结构可控的多孔聚合物微球制备方法及其应用。The invention relates to the fields of polymer material technology and biomedical materials, in particular to a method for preparing porous polymer microspheres with controllable structure and its application.
背景技术Background technique
生物分子在临床治疗中的应用是近年来的一大研究热点。然而,大多数生物分子血浆半衰期短且生物利用度低,这使它难以被有效地用于临床。制备微米级或纳米级的聚合物微球作为生物分子载体,能实现生物分子的高效利用。载体可实现生物分子的可控释放,并能对不稳定的生物活性分子起到保护作用,避免其降解。可降解的天然高分子和合成高分子在药物控释领域都被广泛研究。在众多高分子中,聚乳酸-羟基乙酸(PLGA)具有良好的生物相容性且可自发地生物降解,因此它用于药物控释具有明显的优势。The application of biomolecules in clinical treatment is a major research hotspot in recent years. However, most biomolecules have a short plasma half-life and low bioavailability, which makes it difficult to be effectively used clinically. The preparation of micron-scale or nano-scale polymer microspheres as biomolecule carriers can realize the efficient utilization of biomolecules. Carriers can realize the controlled release of biomolecules and can protect unstable bioactive molecules from degradation. Both degradable natural polymers and synthetic polymers have been extensively studied in the field of controlled drug release. Among many polymers, polylactic-glycolic acid (PLGA) has good biocompatibility and spontaneous biodegradation, so it has obvious advantages in drug controlled release.
单组分微球可以实现一类单个或多个生物分子的传递,并能对生物分子实现长效的控制释放,但是其对生物分子的释放曲线是类似的。这限制了其应用,因为组织和器官的再生通常是由不同的生物分子在不同生长期和成熟阶段对细胞的协同作用所驱动的。因此,为了使受损的、病变的及被移除的组织再生,需要设计并结合具有不同释放性能的微球实现不同生物分子的传递。改变聚合物的聚合度是调节微球释放曲线的最常用方法。控制聚合度不但需要精巧的合成技术,而且难以较为明显地改变释放速率。Single-component microspheres can deliver a class of single or multiple biomolecules, and can achieve long-term controlled release of biomolecules, but their release curves for biomolecules are similar. This limits its applications, since regeneration of tissues and organs is often driven by the synergistic effect of different biomolecules on cells at different growth and maturation stages. Therefore, in order to regenerate damaged, diseased and removed tissues, it is necessary to design and combine microspheres with different release properties to achieve the delivery of different biomolecules. Changing the degree of polymerization of the polymer is the most common way to adjust the release profile of microspheres. Controlling the degree of polymerization not only requires sophisticated synthesis techniques, but also makes it difficult to change the release rate significantly.
近年来,各种乳液法制备的多孔聚合物微球在医疗保健领域有非常广泛的应用。这些方法可以制备出孔结构为开孔(快速释放)和闭合孔(缓慢释放)的聚合物微球,进而能有效地调节生物分子的释放速率。由于这两种不同孔结构的微球的释放性能是互补的,那么将两者结合起来实现不同生物分子的依次释放就是使组织器官再生的一种有效方法。然而,形成多孔结构的传统方法需要在制备乳化液过程中,嵌入和去除硬(软)模板(致孔剂)。这不仅使合成工艺变得复杂化,而且会破坏聚合物基质。除此之外,由于乳化液内部水与外部水的迅速聚集,很难直接制备闭合孔结构的多孔微球。因此,通常需要对开孔结构的多孔微球进行热处理或溶剂处理,才能使其表面孔闭合,进而制得闭合孔结构的微球。因此,开孔和闭孔多孔微球的结合通常需要多个步骤完成。为了便于实际生产和应用中制备大量的不同孔结构的多孔微球,就需要研究出更加简单可行的方法。In recent years, porous polymer microspheres prepared by various emulsion methods have been widely used in the field of medical care. These methods can prepare polymer microspheres with open pores (fast release) and closed pores (slow release), which can effectively regulate the release rate of biomolecules. Since the release properties of these two microspheres with different pore structures are complementary, combining the two to realize the sequential release of different biomolecules is an effective method for tissue and organ regeneration. However, conventional methods for forming porous structures require the embedding and removal of hard (soft) templates (porogens) during the emulsion preparation process. This not only complicates the synthesis process but also damages the polymer matrix. In addition, due to the rapid accumulation of water inside and outside the emulsion, it is difficult to directly prepare porous microspheres with closed pore structure. Therefore, it is usually necessary to heat-treat or solvent-treat porous microspheres with an open-pore structure to close the surface pores, thereby obtaining microspheres with a closed-pore structure. Therefore, the combination of open-cell and closed-cell porous microspheres usually requires multiple steps to complete. In order to facilitate the preparation of a large number of porous microspheres with different pore structures in practical production and application, it is necessary to develop a simpler and more feasible method.
发明内容Contents of the invention
针对以上现有技术中的问题,本发明的目的在于提供一种简单的可一步完成的结构可控的多孔聚合物微球制备方法及其应用,该方法简单易行,反应经一步即可完成,可用于大规模生产,并且制备的微球可用于构筑生物医用材料,如凝胶贴片、支架材料,并将其用于皮肤修复及骨组织修复。In view of the above problems in the prior art, the purpose of the present invention is to provide a simple one-step process for preparing porous polymer microspheres with controllable structure and its application. The method is simple and easy, and the reaction can be completed in one step. , can be used for large-scale production, and the prepared microspheres can be used to construct biomedical materials, such as gel patches, scaffold materials, and used for skin repair and bone tissue repair.
为实现上述目的,本发明采用如下的技术方案:To achieve the above object, the present invention adopts the following technical solutions:
一种结构可控的多孔聚合物微球制备方法,将环糊精溶液与聚乙二醇溶液混合后,加入到PLGA的二氯甲烷溶液中,超声得到水/油乳化液,将水/油乳化液加入到PVA溶液中,超声得到水/油/水乳化液,将水/油/水乳化液在室温下搅拌后,水洗,冷冻干燥得到多孔聚合物微球。A method for preparing porous polymer microspheres with controllable structure. After mixing the cyclodextrin solution and the polyethylene glycol solution, adding it to the dichloromethane solution of PLGA, ultrasonically obtaining a water/oil emulsion, and mixing the water/oil The emulsion is added to the PVA solution, ultrasonically obtained to obtain a water/oil/water emulsion, and the water/oil/water emulsion is stirred at room temperature, washed with water, and freeze-dried to obtain porous polymer microspheres.
本发明进一步的改进在于,环糊精溶液是将环糊精加入到水中制得,环糊精溶液的浓度为3~15mg/mL;环糊精为α-环糊精、β-环糊精、γ-环糊精中的任意一种;The further improvement of the present invention is that the cyclodextrin solution is prepared by adding cyclodextrin into water, and the concentration of the cyclodextrin solution is 3-15 mg/mL; the cyclodextrin is α-cyclodextrin, β-cyclodextrin , any one of γ-cyclodextrin;
聚乙二醇溶液是将聚乙二醇加入到水中制得,聚乙二醇溶液的浓度为50~150mg/mL;聚乙二醇的摩尔质量为2000~50000g;Polyethylene glycol solution is prepared by adding polyethylene glycol into water, the concentration of polyethylene glycol solution is 50-150mg/mL; the molar mass of polyethylene glycol is 2000-50000g;
PLGA的二氯甲烷溶液是将PLGA加入到二氯甲烷中制得,PLGA的二氯甲烷溶液的质量浓度为50~300mg/mL;The methylene chloride solution of PLGA is prepared by adding PLGA to methylene chloride, and the mass concentration of the methylene chloride solution of PLGA is 50-300mg/mL;
PVA溶液是将PVA加入到水中制得,PVA溶液的质量浓度为5~20mg/mL;PVA的摩尔质量为15000~120000g。The PVA solution is prepared by adding PVA to water, the mass concentration of the PVA solution is 5-20 mg/mL; the molar mass of the PVA is 15000-120000 g.
本发明进一步的改进在于,环糊精为α-环糊精。A further improvement of the present invention is that the cyclodextrin is α-cyclodextrin.
本发明进一步的改进在于,超声的功率为10~100W,超声的时间为10~60s;搅拌的时间为1~48h;The further improvement of the present invention is that the ultrasonic power is 10-100W, the ultrasonic time is 10-60s; the stirring time is 1-48h;
环糊精、聚乙二醇、PLGA与PVA的质量比为0.656:7.25:100:100。The mass ratio of cyclodextrin, polyethylene glycol, PLGA and PVA is 0.656:7.25:100:100.
本发明进一步的改进在于,搅拌的时间为3h。A further improvement of the present invention is that the stirring time is 3 hours.
本发明进一步的改进在于,搅拌的时间为24h。A further improvement of the present invention is that the stirring time is 24 hours.
一种多孔聚合物微球在制备用于修复皮肤的凝胶贴片中的应用。Application of a porous polymer microsphere in the preparation of a gel patch for repairing skin.
本发明进一步的改进在于,用于修复皮肤的凝胶贴片的制备方法如下:A further improvement of the present invention is that the preparation method of the gel patch for repairing the skin is as follows:
将环糊精溶液与聚乙二醇溶液混合后,加入到PLGA的二氯甲烷溶液中,超声得到水/油乳化液,将水/油乳化液加入到PVA溶液中,超声得到水/油/水乳化液,将水/油/水乳化液在室温下搅拌3h后,水洗,冷冻干燥,得到闭孔结构的多孔聚合物微球;After mixing the cyclodextrin solution and the polyethylene glycol solution, add it to the dichloromethane solution of PLGA, ultrasonically obtain the water/oil emulsion, add the water/oil emulsion to the PVA solution, and ultrasonically obtain the water/oil/oil emulsion. Water emulsion, stirring the water/oil/water emulsion at room temperature for 3 hours, washing with water, and freeze-drying to obtain porous polymer microspheres with closed-cell structure;
将环糊精溶液与聚乙二醇溶液混合后,加入到PLGA的二氯甲烷溶液中,超声得到水/油乳化液,将水/油乳化液加入到PVA溶液中,超声得到水/油/水乳化液,将水/油/水乳化液在室温下搅拌24h后,水洗,冷冻干燥,得到开孔结构的多孔聚合物微球;After mixing the cyclodextrin solution and the polyethylene glycol solution, add it to the dichloromethane solution of PLGA, ultrasonically obtain the water/oil emulsion, add the water/oil emulsion to the PVA solution, and ultrasonically obtain the water/oil/oil emulsion. Water emulsion, stirring the water/oil/water emulsion at room temperature for 24 hours, washing with water, and freeze-drying to obtain porous polymer microspheres with an open-pore structure;
分别取闭孔结构的多孔聚合物微球和开孔结构的多孔聚合物微球分散在海藻酸钠溶液中,然后均匀铺展在载玻片上,再将滴加氯化钙溶液,用另一块载玻片压制,得到凝胶贴片;其中,闭孔结构的多孔聚合物微球、开孔结构的多孔聚合物微球与海藻酸钠溶液的比为10mg:10mg:300μL。The porous polymer microspheres with closed-pore structure and the porous polymer microspheres with open-pore structure were respectively dispersed in sodium alginate solution, and then evenly spread on the glass slide, and then the calcium chloride solution was added dropwise, and another slide was used. The glass slide was pressed to obtain a gel patch; wherein, the ratio of the closed-pore porous polymer microspheres, the open-pore porous polymer microspheres to the sodium alginate solution was 10 mg: 10 mg: 300 μL.
本发明进一步的改进在于,用于修复皮肤的凝胶贴片的制备方法如下:A further improvement of the present invention is that the preparation method of the gel patch for repairing the skin is as follows:
将环糊精溶液与聚乙二醇溶液混合后,加入到PLGA的二氯甲烷溶液中,超声得到水/油乳化液,将水/油乳化液加入到PVA溶液中,超声得到水/油/水乳化液,将水/油/水乳化液在室温下搅拌3h后,水洗,冷冻干燥,得到闭孔结构的多孔聚合物微球;After mixing the cyclodextrin solution and the polyethylene glycol solution, add it to the dichloromethane solution of PLGA, ultrasonically obtain the water/oil emulsion, add the water/oil emulsion to the PVA solution, and ultrasonically obtain the water/oil/oil emulsion. Water emulsion, stirring the water/oil/water emulsion at room temperature for 3 hours, washing with water, and freeze-drying to obtain porous polymer microspheres with closed-cell structure;
将闭孔结构的多孔聚合物微球分散在去离子水中,加入白介素,在冰浴下搅拌24h后冻干燥,得到装载有白介素的微球;其中,闭孔结构的多孔聚合物微球、去离子水与白介素的比为20mg:5mL:10mg;Disperse the porous polymer microspheres with closed-cell structure in deionized water, add interleukin, stir in an ice bath for 24 hours, and freeze-dry to obtain microspheres loaded with interleukin; wherein, the porous polymer microspheres with closed-cell structure, deionized The ratio of ionized water to interleukin is 20mg: 5mL: 10mg;
取上述装载有白介素的微球分散在海藻酸钠溶液中,然后均匀铺展在载玻片上,再滴加氯化钙溶液,用另一块载玻片压制30min,得到凝胶贴片;其中,装载有白介素的微球与海藻酸钠溶液的比为20mg:300μL。Disperse the above-mentioned microspheres loaded with interleukin in sodium alginate solution, spread evenly on a glass slide, then add calcium chloride solution dropwise, and press another piece of glass slide for 30 minutes to obtain a gel patch; The ratio of interleukin-containing microspheres to sodium alginate solution is 20mg: 300μL.
本发明进一步的改进在于,将褪黑素溶于聚乙二醇溶液中,再与环糊精溶液混合均匀,加入到PLGA的二氯甲烷溶液中,超声,形成水/油乳化液;将上述水/油乳化液加入到PVA溶液中,超声得到水/油/水乳化液,将此乳化液在室温下搅拌3h,水洗,冷冻干燥,得到含褪黑素的内部多孔的聚合物微球;其中,褪黑素与聚乙二醇的比为10mg:7.25mg;The further improvement of the present invention is that melatonin is dissolved in polyethylene glycol solution, then mixed with cyclodextrin solution evenly, added to the dichloromethane solution of PLGA, and ultrasonicated to form a water/oil emulsion; The water/oil emulsion is added to the PVA solution, and the water/oil/water emulsion is obtained by ultrasonication. The emulsion is stirred at room temperature for 3 hours, washed with water, and freeze-dried to obtain internally porous polymer microspheres containing melatonin; Among them, the ratio of melatonin to polyethylene glycol is 10mg: 7.25mg;
取含褪黑素的内部多孔的聚合物微球分散在海藻酸钠溶液中,然后均匀铺展在载玻片上,再滴加氯化钙溶液,用另一块载玻片压制,得到凝胶贴片;其中,含褪黑素的内部多孔的聚合物微球与海藻酸钠溶液的比为20mg:300μL。Disperse the internal porous polymer microspheres containing melatonin in sodium alginate solution, spread evenly on a glass slide, then add calcium chloride solution dropwise, and press with another glass slide to obtain a gel patch ; Wherein, the ratio of the internal porous polymer microspheres containing melatonin to the sodium alginate solution is 20 mg: 300 μL.
本发明进一步的改进在于,将环糊精溶液与聚乙二醇溶液混合后,加入到PLGA的二氯甲烷溶液中,超声得到水/油乳化液,将水/油乳化液加入到PVA溶液中,超声得到水/油/水乳化液,将水/油/水乳化液在室温下搅拌3h后,水洗,冷冻干燥,得到闭孔结构的多孔聚合物微球;将闭孔结构的多孔聚合物微球分散在去离子水中,加入白介素,在冰浴下搅拌24h后冻干燥,得到装载有白介素的微球;其中,闭孔结构的多孔聚合物微球、去离子水与白介素的比为20mg:5mL:10mg;The further improvement of the present invention is that, after mixing the cyclodextrin solution and the polyethylene glycol solution, add it to the dichloromethane solution of PLGA, ultrasonically obtain the water/oil emulsion, and add the water/oil emulsion to the PVA solution , ultrasonically obtained water/oil/water emulsion, after stirring the water/oil/water emulsion at room temperature for 3h, washing with water, and freeze-drying to obtain porous polymer microspheres with closed-cell structure; the porous polymer microspheres with closed-cell structure Microspheres are dispersed in deionized water, interleukin is added, stirred in an ice bath for 24 hours, and then freeze-dried to obtain microspheres loaded with interleukin; wherein, the ratio of closed-cell porous polymer microspheres, deionized water to interleukin is 20mg : 5mL: 10mg;
将褪黑素溶于聚乙二醇溶液中,再与环糊精溶液混合均匀,加入到PLGA的二氯甲烷溶液中,超声,形成水/油乳化液;将上述水/油乳化液加入到PVA溶液中,超声得到水/油/水乳化液,将此乳化液在室温下搅拌3h,水洗,冷冻干燥,得到含褪黑素的内部多孔的聚合物微球;其中,褪黑素与聚乙二醇的比为10mg:7.25mg;Dissolve melatonin in polyethylene glycol solution, mix evenly with cyclodextrin solution, add it to the dichloromethane solution of PLGA, and ultrasonicate to form a water/oil emulsion; add the above water/oil emulsion to In the PVA solution, the water/oil/water emulsion was obtained by ultrasound, and the emulsion was stirred at room temperature for 3 hours, washed with water, and freeze-dried to obtain internal porous polymer microspheres containing melatonin; wherein, melatonin and poly The ratio of ethylene glycol is 10mg: 7.25mg;
分别将装载有白介素的微球与含褪黑素的内部多孔的聚合物微球分散在海藻酸钠溶液中,然后均匀铺展在载玻片上,再滴加氯化钙溶液,用另一块载玻片压制,得到凝胶贴片;其中,装载有白介素的微球、含褪黑素的内部多孔的聚合物微球与海藻酸钠溶液的比为10mg:10mg:300μL。Disperse the interleukin-loaded microspheres and melatonin-containing internal porous polymer microspheres in sodium alginate solution, spread evenly on a glass slide, then add calcium chloride solution dropwise, and use another glass slide The tablet was compressed to obtain a gel patch; wherein, the ratio of interleukin-loaded microspheres, melatonin-containing internal porous polymer microspheres, and sodium alginate solution was 10 mg: 10 mg: 300 μL.
本发明进一步的改进在于,闭孔结构的多孔聚合物微球与开孔结构的多孔聚合物微球的总和、装载有白介素的微球以及含褪黑素的内部多孔的聚合物微球与海藻酸钠溶液的比为10mg~40mg:500μL。The further improvement of the present invention is that the sum of the porous polymer microspheres of the closed-pore structure and the porous polymer microspheres of the open-pore structure, the microspheres loaded with interleukin and the internal porous polymer microspheres containing melatonin and seaweed The ratio of sodium bicarbonate solution is 10mg ~ 40mg: 500μL.
本发明进一步的改进在于,海藻酸钠质量浓度为10~30mg/mL。The further improvement of the present invention lies in that the mass concentration of sodium alginate is 10-30 mg/mL.
本发明进一步的改进在于,氯化钙浓度为0.2~0.8mol/L。The further improvement of the present invention lies in that the calcium chloride concentration is 0.2-0.8 mol/L.
与现有技术相比,本发明具有的有益效果:Compared with the prior art, the present invention has the beneficial effects:
1.本发明采用的聚合物微球基质PLGA(聚乳酸-羟基乙酸),来源广泛,生物相容性好,可降解,且降解产物无毒,适用于生物医学领域中,本发明以PLGA作为多孔微球基底,结合双乳化法与溶胶-凝胶法,通过控制乳化液熟化时间,经过一步反应制备出了具有不同孔结构的多孔微球,并且制得的多孔聚合物微球粒度是微米级,平均粒径为2~5μm,分散度和球形度均好。本发明中搅拌的时间长短可以控制多孔聚合物微球的孔结构,搅拌时间短的话,微球表面没有孔,搅拌时间长的话,微球表面有孔。1. The polymer microsphere matrix PLGA (polylactic acid-glycolic acid) that the present invention adopts has a wide range of sources, good biocompatibility, degradable, and degradation products are nontoxic, and is applicable to the field of biomedicine. The present invention uses PLGA as The porous microsphere substrate, combined with the double emulsion method and the sol-gel method, controlled the aging time of the emulsion, and prepared porous microspheres with different pore structures through a one-step reaction, and the particle size of the prepared porous polymer microspheres was micron grade, with an average particle size of 2-5 μm, good dispersion and sphericity. The length of stirring time in the present invention can control the pore structure of the porous polymer microsphere. If the stirring time is short, the surface of the microsphere has no pores; if the stirring time is long, the surface of the microsphere has pores.
2.本发明采用双乳化法与溶胶凝胶法相结合的方法,通过控制乳化液熟化时间,仅用一步反应就制备出了具有不同孔结构的多孔聚合物微球,制备方法简单,易于实现工业化生产。2. The present invention adopts the method of combining double emulsification method and sol-gel method. By controlling the aging time of the emulsion, porous polymer microspheres with different pore structures are prepared in only one step reaction. The preparation method is simple and easy to realize industrialization Production.
3.本发明反应周期短,产率高,能有效提高工作效率。3. The present invention has short reaction cycle and high yield, and can effectively improve work efficiency.
4.本发明在操作过程中不产生有机废液,是一种绿色环保的制备方法。4. The present invention does not generate organic waste liquid during the operation process, and is a green and environment-friendly preparation method.
5.本发明无需用到大型昂贵的仪器设备,生产成本低。5. The present invention does not need to use large and expensive instruments and equipment, and the production cost is low.
6.本发明制备的不同结构的多孔微球有许多用途,如作为生物分子载体用于组织器官的再生,作为抗菌药物载体以提高抗菌药物的抗菌能力等等。在生物医用材料构筑方面的应用,如制备用于皮肤修复的凝胶贴片,对于皮肤修复有较好的效果。6. The porous microspheres of different structures prepared by the present invention have many uses, such as being used as a biomolecular carrier for the regeneration of tissues and organs, as an antibacterial drug carrier to improve the antibacterial ability of antibacterial drugs, and the like. The application in the construction of biomedical materials, such as the preparation of gel patches for skin repair, has a good effect on skin repair.
附图说明Description of drawings
图1是实施例2提供的闭合孔结构的多孔微球。Figure 1 is the porous microsphere with closed pore structure provided by Example 2.
图2为图1中的局部放大图。FIG. 2 is a partially enlarged view of FIG. 1 .
图3是实施例4提供的开孔结构的多孔微球。Fig. 3 is the porous microsphere with open-pore structure provided by Example 4.
图4为图3中的局部放大图。FIG. 4 is a partially enlarged view of FIG. 3 .
图5是实施例11与实施例12提供的闭合孔结构的多孔微球和开孔结构的多孔微球对FITC-BSA的释放曲线。Fig. 5 is the release curve of FITC-BSA by the porous microspheres with closed pore structure and porous microspheres with open pore structure provided in Example 11 and Example 12.
图6是实施例17提供的小鼠伤口愈合情况图。Fig. 6 is a diagram of wound healing in mice provided in Example 17.
图7是实施例17提供的小鼠创伤面愈合率统计图。FIG. 7 is a statistical chart of the wound healing rate of mice provided in Example 17. FIG.
图8是实施例17提供的吞噬细胞迁移分化的效果图。FIG. 8 is an effect diagram of the migration and differentiation of phagocytic cells provided in Example 17.
图9是实施例17提供的CD206阳性巨噬细胞数量统计图。FIG. 9 is a statistical diagram of the number of CD206-positive macrophages provided in Example 17. FIG.
图10是实施例17提供的血管内皮生长因子(VEGF)数量统计值。Figure 10 is the statistical value of vascular endothelial growth factor (VEGF) provided by Example 17.
图11是实施例17提供的血管紧张素Ⅱ(AngⅡ)数量统计值。FIG. 11 is the statistical value of angiotensin II (Ang II) provided in Example 17.
具体实施方式detailed description
下面结合实施例和附图对本发明做进一步说明,但不限于此。The present invention will be further described below in conjunction with the embodiments and drawings, but not limited thereto.
本发明涉及一步法制备不同结构的聚合物微球及以此聚合物微球为基础的生物医用材料的构筑和应用。The invention relates to one-step preparation of polymer microspheres with different structures and the construction and application of biomedical materials based on the polymer microspheres.
一种结构可控的多孔聚合物微球制备方法,将环糊精加入到水中,得到环糊精溶液,将聚乙二醇(PEG)加入到水中,得到聚乙二醇溶液,将环糊精溶液与聚乙二醇溶液混合后,加入到PLGA(聚乳酸-羟基乙酸)的二氯甲烷溶液中,超声得到水/油乳化液,将水/油乳化液加入到聚乙烯醇(PVA)的溶液中,在10~100W下超声10~60s,得到水/油/水乳化液,将水/油/水乳化液在室温下搅拌1~48h后,水洗3~5次,冷冻干燥,得到多孔聚合物微球。A method for preparing porous polymer microspheres with controllable structure, adding cyclodextrin to water to obtain cyclodextrin solution, adding polyethylene glycol (PEG) to water to obtain polyethylene glycol solution, and cyclodextrin After the fine solution is mixed with the polyethylene glycol solution, it is added to the dichloromethane solution of PLGA (polylactic acid-glycolic acid), and the water/oil emulsion is obtained by ultrasonication, and the water/oil emulsion is added to polyvinyl alcohol (PVA) In the solution of 10-100W, ultrasonication is performed for 10-60s to obtain water/oil/water emulsion, and the water/oil/water emulsion is stirred at room temperature for 1-48h, washed with water for 3-5 times, and freeze-dried to obtain Porous polymer microspheres.
所述的环糊精为α-环糊精、β-环糊精、γ-环糊精中的任意一种。The cyclodextrin is any one of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin.
优选的,所述的环糊精为α-环糊精。环糊精溶液的浓度为3~10mg/mL。Preferably, the cyclodextrin is α-cyclodextrin. The concentration of the cyclodextrin solution is 3-10 mg/mL.
所述的聚乙二醇(PEG)摩尔质量为2000~50000g,聚乙二醇溶液的浓度为50~90mg/mL。The molar mass of the polyethylene glycol (PEG) is 2000-50000 g, and the concentration of the polyethylene glycol solution is 50-90 mg/mL.
所述的PLGA的二氯甲烷溶液的质量浓度为5%~30%。The mass concentration of the PLGA dichloromethane solution is 5%-30%.
所述的PVA摩尔质量为15000~120000g,聚乙烯醇的溶液的质量浓度为0.5%~2%。The molar mass of the PVA is 15000-120000g, and the mass concentration of the polyvinyl alcohol solution is 0.5%-2%.
本发明制得的多孔聚合物微球粒度是微米级,平均粒径为2~5μm。分散度和球形度均好。The particle size of the porous polymer microsphere prepared by the invention is in the order of microns, and the average particle size is 2-5 μm. Both dispersion and sphericity are good.
本发明的实施例1-17中使用的PLGA摩尔质量为64000g,乳酸/羟基乙酸=50/50;使用的PVA摩尔质量为25000g,醇解度为88%;PEG摩尔质量为2000g,环糊精为α-环糊精。The molar mass of PLGA used in Examples 1-17 of the present invention is 64000g, lactic acid/glycolic acid=50/50; the molar mass of PVA used is 25000g, and the degree of alcoholysis is 88%; the molar mass of PEG is 2000g, cyclodextrin For α-cyclodextrin.
实施例1Example 1
称取100mg的PLGA溶于1mL二氯甲烷中,配制10%(w/v)的PLGA的二氯甲烷溶液。称取13.12mgα-环糊精溶于1mL水中,配制13.12mg/mL的α-环糊精溶液;称取145mg PEG-2000溶于1mL水中,配制145mg/mL的PEG溶液。取2g PVA溶于200mL水中,配制1%(w/v)的PVA溶液。100 mg of PLGA was weighed and dissolved in 1 mL of dichloromethane to prepare a 10% (w/v) solution of PLGA in dichloromethane. Weigh 13.12mg α-cyclodextrin and dissolve it in 1mL water to prepare 13.12mg/mL α-cyclodextrin solution; weigh 145mg PEG-2000 and dissolve it in 1mL water to prepare 145mg/mL PEG solution. Dissolve 2g of PVA in 200mL of water to prepare a 1% (w/v) PVA solution.
取50μL 13.12mg/mL的α-环糊精溶液与50μL 145mg/mL的PEG溶液混合均匀,加入到1mL 10%(w/v)的PLGA的二氯甲烷溶液中,以15W功率超声20s,形成水/油乳化液;将上述水/油乳化液加入到10mL 1%(w/v)的PVA溶液中,超声得到水/油/水乳化液。将此乳化液在室温下200~600r/min缓慢搅拌1h,水洗3次,冷冻干燥,得到多孔聚合物微球。此条件下得到的微球表面无孔而内部有孔,内部孔较少且孔分散不均匀。Take 50 μL of 13.12 mg/mL α-cyclodextrin solution and 50 μL of 145 mg/mL PEG solution, mix evenly, add to 1 mL of 10% (w/v) PLGA in dichloromethane solution, and sonicate at 15W for 20s to form Water/oil emulsion: the above water/oil emulsion was added to 10 mL of 1% (w/v) PVA solution, and the water/oil/water emulsion was obtained by ultrasonication. The emulsion was slowly stirred at room temperature at 200-600 r/min for 1 hour, washed with water three times, and freeze-dried to obtain porous polymer microspheres. The microspheres obtained under this condition have no pores on the surface but internal pores, and the internal pores are less and the pores are not uniformly dispersed.
实施例2Example 2
称取100mg的PLGA溶于1mL二氯甲烷中,配制10%(w/v)的PLGA的二氯甲烷溶液。称取13.12mgα-环糊精溶于1mL水中,配制13.12mg/mL的α-环糊精溶液;称取145mg PEG-2000溶于1mL水中,配制145mg/mL的PEG溶液。取2g PVA溶于200mL水中,配制1%(w/v)的PVA溶液。100 mg of PLGA was weighed and dissolved in 1 mL of dichloromethane to prepare a 10% (w/v) solution of PLGA in dichloromethane. Weigh 13.12mg α-cyclodextrin and dissolve it in 1mL water to prepare 13.12mg/mL α-cyclodextrin solution; weigh 145mg PEG-2000 and dissolve it in 1mL water to prepare 145mg/mL PEG solution. Dissolve 2g of PVA in 200mL of water to prepare a 1% (w/v) PVA solution.
取50μL 13.12mg/mL的α-环糊精溶液与50μL 145mg/mL的PEG溶液混合均匀,加入到1mL 10%(w/v)的PLGA的二氯甲烷溶液中,以15W功率超声20s,形成水/油乳化液;将上述水/油乳化液加入到10mL 1%(w/v)的PVA溶液中,超声得到水/油/水乳化液。将此乳化液在室温下200~600r/min下缓慢搅拌3h,水洗3次,冷冻干燥,即得到多孔聚合物微球。微球的扫描电镜如图1和图2。由图1和图2可知乳化液熟化3h得到的微球表面无孔而内部有孔,即为闭孔结构,微球粒径在5μm左右。Take 50 μL of 13.12 mg/mL α-cyclodextrin solution and 50 μL of 145 mg/mL PEG solution, mix evenly, add to 1 mL of 10% (w/v) PLGA in dichloromethane solution, and sonicate at 15W for 20s to form Water/oil emulsion: the above water/oil emulsion was added to 10 mL of 1% (w/v) PVA solution, and the water/oil/water emulsion was obtained by ultrasonication. The emulsion was slowly stirred at room temperature at 200-600 r/min for 3 hours, washed with water three times, and freeze-dried to obtain porous polymer microspheres. The scanning electron microscope of the microspheres is shown in Figure 1 and Figure 2. It can be seen from Figure 1 and Figure 2 that the microspheres obtained by aging the emulsion for 3 hours have no pores on the surface and pores inside, that is, a closed-cell structure, and the particle size of the microspheres is about 5 μm.
实施例3Example 3
称取100mg的PLGA溶于1mL二氯甲烷中,配制10%(w/v)的PLGA的二氯甲烷溶液。称取13.12mgα-环糊精溶于1mL水中,配制13.12mg/mL的α-环糊精溶液;称取145mg PEG-2000溶于1mL水中,配制145mg/mL的PEG溶液。取2g PVA溶于200mL水中,配制1%(w/v)的PVA的二氯甲烷溶液。100 mg of PLGA was weighed and dissolved in 1 mL of dichloromethane to prepare a 10% (w/v) solution of PLGA in dichloromethane. Weigh 13.12mg α-cyclodextrin and dissolve it in 1mL water to prepare 13.12mg/mL α-cyclodextrin solution; weigh 145mg PEG-2000 and dissolve it in 1mL water to prepare 145mg/mL PEG solution. 2 g of PVA was dissolved in 200 mL of water to prepare a 1% (w/v) solution of PVA in dichloromethane.
取50μL 13.12mg/mL的α-环糊精溶液与50μL 145mg/mL的PEG溶液混合均匀,加入到1mL 10%(w/v)的PLGA溶液中,以15W功率超声20s,形成水/油乳化液;将上述水/油乳化液加入到10mL 1%(w/v)的PVA溶液中,超声得到水/油/水乳化液。将此乳化液在室温下200~600r/min下缓慢搅拌12h,水洗3次,冷冻干燥,得到多孔聚合物微球。此条件下得到的微球表面无孔而内部有孔,孔径较大。Take 50 μL of 13.12 mg/mL α-cyclodextrin solution and 50 μL of 145 mg/mL PEG solution, mix evenly, add to 1 mL of 10% (w/v) PLGA solution, and ultrasonicate for 20 seconds at 15W to form a water/oil emulsion Liquid; the above-mentioned water/oil emulsion was added to 10 mL of 1% (w/v) PVA solution, and the water/oil/water emulsion was obtained by ultrasonication. The emulsion was slowly stirred at room temperature at 200-600 r/min for 12 hours, washed with water three times, and freeze-dried to obtain porous polymer microspheres. The microspheres obtained under this condition have no pores on the surface and pores inside, and the pore diameter is relatively large.
实施例4Example 4
称取100mg的PLGA溶于1mL二氯甲烷中,配制10%(w/v)的PLGA的二氯甲烷溶液。称取13.12mgα-环糊精溶于1mL水中,配制13.12mg/mL的α-环糊精溶液;称取145mg PEG-2000溶于1mL水中,配制145mg/mL的PEG溶液。取2g PVA溶于200mL水中,配制1%(w/v)的PVA的二氯甲烷溶液。100 mg of PLGA was weighed and dissolved in 1 mL of dichloromethane to prepare a 10% (w/v) solution of PLGA in dichloromethane. Weigh 13.12mg α-cyclodextrin and dissolve it in 1mL water to prepare 13.12mg/mL α-cyclodextrin solution; weigh 145mg PEG-2000 and dissolve it in 1mL water to prepare 145mg/mL PEG solution. 2 g of PVA was dissolved in 200 mL of water to prepare a 1% (w/v) solution of PVA in dichloromethane.
取50μL 13.12mg/mL的α-环糊精溶液与50μL 145mg/mL的PEG溶液混合均匀,加入到1mL 10%(w/v)的PLGA溶液中,以15W功率超声20s,形成水/油乳化液;将上述水/油乳化液加入到10mL 1%(w/v)的PVA溶液中,超声得到水/油/水乳化液。将此乳化液在室温下200~600r/min下缓慢搅拌24h,水洗3次,冷冻干燥,即得到多孔聚合物微球。微球的扫描电镜如图3和图4。由图3和图4可知,乳化液熟化24h得到的微球为开孔结构,即微球表面与内部都有孔,微球粒径在5μm左右。Take 50 μL of 13.12 mg/mL α-cyclodextrin solution and 50 μL of 145 mg/mL PEG solution, mix evenly, add to 1 mL of 10% (w/v) PLGA solution, and ultrasonicate for 20 seconds at 15W to form a water/oil emulsion Liquid; the above-mentioned water/oil emulsion was added to 10 mL of 1% (w/v) PVA solution, and the water/oil/water emulsion was obtained by ultrasonication. The emulsion was slowly stirred at room temperature at 200-600 r/min for 24 hours, washed with water three times, and freeze-dried to obtain porous polymer microspheres. The scanning electron microscope of the microspheres is shown in Figure 3 and Figure 4. It can be seen from Figure 3 and Figure 4 that the microspheres obtained by aging the emulsion for 24 hours have an open-pore structure, that is, there are pores on the surface and inside of the microspheres, and the particle size of the microspheres is about 5 μm.
实施例5Example 5
称取100mg的PLGA溶于1mL二氯甲烷中,配制10%(w/v)的PLGA的二氯甲烷溶液。称取13.12mgα-环糊精溶于1mL水中,配制13.12mg/mL的α-环糊精溶液;称取145mg PEG-2000溶于1mL水中,配制145mg/mL的PEG溶液。取2g PVA溶于200mL水中,配制1%(w/v)的PVA的二氯甲烷溶液。100 mg of PLGA was weighed and dissolved in 1 mL of dichloromethane to prepare a 10% (w/v) solution of PLGA in dichloromethane. Weigh 13.12mg α-cyclodextrin and dissolve it in 1mL water to prepare 13.12mg/mL α-cyclodextrin solution; weigh 145mg PEG-2000 and dissolve it in 1mL water to prepare 145mg/mL PEG solution. 2 g of PVA was dissolved in 200 mL of water to prepare a 1% (w/v) solution of PVA in dichloromethane.
取50μL 13.12mg/mL的α-环糊精溶液与50μL 145mg/mL的PEG溶液混合均匀,加入到1mL 10%(w/v)的PLGA溶液中,以15W功率超声20s,形成水/油乳化液;将上述水/油乳化液加入到10mL 1%(w/v)的PVA溶液中,超声得到水/油/水乳化液。将此乳化液在室温下200~600r/min下缓慢搅拌36h,水洗3次,冷冻干燥,得到多孔聚合物微球。Take 50 μL of 13.12 mg/mL α-cyclodextrin solution and 50 μL of 145 mg/mL PEG solution, mix evenly, add to 1 mL of 10% (w/v) PLGA solution, and ultrasonicate for 20 seconds at 15W to form a water/oil emulsion Liquid; the above-mentioned water/oil emulsion was added to 10 mL of 1% (w/v) PVA solution, and the water/oil/water emulsion was obtained by ultrasonication. The emulsion was slowly stirred at room temperature at 200-600 r/min for 36 hours, washed with water three times, and freeze-dried to obtain porous polymer microspheres.
实施例6Example 6
称取100mg的PLGA溶于1mL二氯甲烷中,配制10%(w/v)的PLGA的二氯甲烷溶液。称取13.12mgα-环糊精溶于1mL水中,配制13.12mg/mL的α-环糊精溶液;称取145mg PEG-2000溶于1mL水中,配制145mg/mL的PEG溶液。取2g PVA溶于200mL水中,配制1%(w/v)的PVA的二氯甲烷溶液。100 mg of PLGA was weighed and dissolved in 1 mL of dichloromethane to prepare a 10% (w/v) solution of PLGA in dichloromethane. Weigh 13.12mg α-cyclodextrin and dissolve it in 1mL water to prepare 13.12mg/mL α-cyclodextrin solution; weigh 145mg PEG-2000 and dissolve it in 1mL water to prepare 145mg/mL PEG solution. 2 g of PVA was dissolved in 200 mL of water to prepare a 1% (w/v) solution of PVA in dichloromethane.
取50μL 13.12mg/mL的α-环糊精溶液与50μL 145mg/mL的PEG溶液混合均匀,加入到1mL 10%(w/v)的PLGA溶液中,以15W功率超声20s,形成水/油乳化液;将上述水/油乳化液加入到10mL 1%(w/v)的PVA溶液中,超声得到水/油/水乳化液。将此乳化液在室温下200-600r/min下缓慢搅拌48h,水洗3次,冷冻干燥,得到多孔聚合物微球。Take 50 μL of 13.12 mg/mL α-cyclodextrin solution and 50 μL of 145 mg/mL PEG solution, mix evenly, add to 1 mL of 10% (w/v) PLGA solution, and ultrasonicate for 20 seconds at 15W to form a water/oil emulsion Liquid; the above-mentioned water/oil emulsion was added to 10 mL of 1% (w/v) PVA solution, and the water/oil/water emulsion was obtained by ultrasonication. The emulsion was slowly stirred at room temperature at 200-600 r/min for 48 hours, washed with water three times, and freeze-dried to obtain porous polymer microspheres.
实施例7Example 7
称取25mg的PLGA溶于1mL二氯甲烷中,配制2.5%(w/v)的PLGA的二氯甲烷溶液。称取13.12mgα-环糊精溶于1mL水中,配制13.12mg/mL的α-环糊精溶液;称取145mg PEG-2000溶于1mL水中,配制145mg/mL的PEG溶液。取2g PVA溶于200mL水中,配制1%(w/v)的PVA溶液。25 mg of PLGA was weighed and dissolved in 1 mL of dichloromethane to prepare a 2.5% (w/v) solution of PLGA in dichloromethane. Weigh 13.12mg α-cyclodextrin and dissolve it in 1mL water to prepare 13.12mg/mL α-cyclodextrin solution; weigh 145mg PEG-2000 and dissolve it in 1mL water to prepare 145mg/mL PEG solution. Dissolve 2g of PVA in 200mL of water to prepare a 1% (w/v) PVA solution.
取50μL 13.12mg/mL的α-环糊精溶液与50μL 145mg/mL的PEG溶液混合均匀,加入到1mL 10%(w/v)的PLGA的二氯甲烷溶液中,以15W功率超声20s,形成水/油乳化液;将上述水/油乳化液加入到10mL 1%的PVA溶液中,超声得到水/油/水乳化液。将此乳化液在室温下200~600r/min下缓慢搅拌3h,水洗3次,冷冻干燥,即得到多孔聚合物微球。Take 50 μL of 13.12 mg/mL α-cyclodextrin solution and 50 μL of 145 mg/mL PEG solution, mix evenly, add to 1 mL of 10% (w/v) PLGA in dichloromethane solution, and sonicate at 15W for 20s to form Water/oil emulsion: Add the above water/oil emulsion into 10mL of 1% PVA solution, and ultrasonically obtain the water/oil/water emulsion. The emulsion was slowly stirred at room temperature at 200-600 r/min for 3 hours, washed with water three times, and freeze-dried to obtain porous polymer microspheres.
实施例8Example 8
称取25mg的PLGA溶于1mL二氯甲烷中,配制2.5%(w/v)的PLGA的二氯甲烷溶液。称取13.12mgα-环糊精溶于1mL水中,配制13.12mg/mL的α-环糊精溶液;称取145mg PEG-2000溶于1mL水中,配制145mg/mL的PEG溶液。取2g PVA溶于200mL水中,配制1%(w/v)的PVA溶液。25 mg of PLGA was weighed and dissolved in 1 mL of dichloromethane to prepare a 2.5% (w/v) solution of PLGA in dichloromethane. Weigh 13.12mg α-cyclodextrin and dissolve it in 1mL water to prepare 13.12mg/mL α-cyclodextrin solution; weigh 145mg PEG-2000 and dissolve it in 1mL water to prepare 145mg/mL PEG solution. Dissolve 2g of PVA in 200mL of water to prepare a 1% (w/v) PVA solution.
取50μL 13.12mg/mL的α-环糊精溶液与50μL 145mg/mL的PEG溶液混合均匀,加入到1mL 10%(w/v)的PLGA的二氯甲烷溶液中,以15W功率超声20s,形成水/油乳化液;将上述水/油乳化液加入到10mL 1%(w/v)的PVA溶液中,超声得到水/油/水乳化液。将此乳化液在室温下200~600r/min下缓慢搅拌24h,水洗3次,冷冻干燥,即得到多孔聚合物微球。Take 50 μL of 13.12 mg/mL α-cyclodextrin solution and 50 μL of 145 mg/mL PEG solution, mix evenly, add to 1 mL of 10% (w/v) PLGA in dichloromethane solution, and sonicate at 15W for 20s to form Water/oil emulsion: the above water/oil emulsion was added to 10 mL of 1% (w/v) PVA solution, and the water/oil/water emulsion was obtained by ultrasonication. The emulsion was slowly stirred at room temperature at 200-600 r/min for 24 hours, washed with water three times, and freeze-dried to obtain porous polymer microspheres.
实施例9Example 9
称取100mg的PLGA溶于1mL二氯甲烷中,配制10%(w/v)的PLGA的二氯甲烷溶液。称取13.12mgα-环糊精溶于1mL水中,配制13.12mg/mL的α-环糊精溶液;称取145mg PEG-2000溶于1mL水中,配制145mg/mL的PEG溶液。取2g PVA溶于200mL水中,配制1%(w/v)的PVA溶液。100 mg of PLGA was weighed and dissolved in 1 mL of dichloromethane to prepare a 10% (w/v) solution of PLGA in dichloromethane. Weigh 13.12mg α-cyclodextrin and dissolve it in 1mL water to prepare 13.12mg/mL α-cyclodextrin solution; weigh 145mg PEG-2000 and dissolve it in 1mL water to prepare 145mg/mL PEG solution. Dissolve 2g of PVA in 200mL of water to prepare a 1% (w/v) PVA solution.
取50μL 13.12mg/mL的α-环糊精溶液与50μL 145mg/mL的PEG的二氯甲烷溶液混合均匀,加入到1mL 10%(w/v)的PLGA溶液中,以50W功率超声20s,形成水/油乳化液;将上述水/油乳化液加入到10mL 1%(w/v)的PVA溶液中,超声得到水/油/水乳化液。将此乳化液在室温下200~600r/min下缓慢搅拌3h,水洗3次,冷冻干燥,即得到多孔聚合物微球。Take 50 μL of 13.12 mg/mL α-cyclodextrin solution and 50 μL of 145 mg/mL PEG solution in dichloromethane, mix evenly, add to 1 mL of 10% (w/v) PLGA solution, and sonicate at 50 W for 20 seconds to form Water/oil emulsion: the above water/oil emulsion was added to 10 mL of 1% (w/v) PVA solution, and the water/oil/water emulsion was obtained by ultrasonication. The emulsion was slowly stirred at room temperature at 200-600 r/min for 3 hours, washed with water three times, and freeze-dried to obtain porous polymer microspheres.
实施例10Example 10
称取100mg的PLGA溶于1mL二氯甲烷中,配制10%(w/v)的PLGA的二氯甲烷溶液。称取13.12mgα-环糊精溶于1mL水中,配制13.12mg/mL的α-环糊精溶液;称取145mg PEG-2000溶于1mL水中,配制145mg/mL的PEG溶液。取2g PVA溶于200mL水中,配制1%(w/v)的PVA溶液。100 mg of PLGA was weighed and dissolved in 1 mL of dichloromethane to prepare a 10% (w/v) solution of PLGA in dichloromethane. Weigh 13.12mg α-cyclodextrin and dissolve it in 1mL water to prepare 13.12mg/mL α-cyclodextrin solution; weigh 145mg PEG-2000 and dissolve it in 1mL water to prepare 145mg/mL PEG solution. Dissolve 2g of PVA in 200mL of water to prepare a 1% (w/v) PVA solution.
取50μL 13.12mg/mL的α-环糊精溶液与50μL 145mg/mL的PEG溶液混合均匀,加入到1mL 10%(w/v)的PLGA的二氯甲烷溶液中,以50W功率超声20s,形成水/油乳化液;将上述水/油乳化液加入到10mL 1%(w/v)的PVA溶液中,超声得到水/油/水乳化液。将此乳化液在室温下200-600r/min下缓慢搅拌24h,水洗3次,冷冻干燥,即得到多孔聚合物微球。Take 50 μL of 13.12 mg/mL α-cyclodextrin solution and 50 μL of 145 mg/mL PEG solution, mix evenly, add to 1 mL of 10% (w/v) PLGA in dichloromethane solution, and sonicate at 50 W for 20 seconds to form Water/oil emulsion: the above water/oil emulsion was added to 10 mL of 1% (w/v) PVA solution, and the water/oil/water emulsion was obtained by ultrasonication. The emulsion was slowly stirred at room temperature at 200-600 r/min for 24 hours, washed with water three times, and freeze-dried to obtain porous polymer microspheres.
实施例11闭孔结构的多孔微球的长效释放能力测试:The long-term release ability test of the porous microsphere of embodiment 11 closed cell structure:
称取100mg的PLGA溶于1mL二氯甲烷中,配制10%(w/v)的PLGA的二氯甲烷溶液。称取13.12mgα-环糊精溶于1mL水中,配制13.12mg/mL的α-环糊精溶液;称取145mg PEG-2000溶于1mL水中,配制145mg/mL的PEG溶液。取2g PVA溶于200mL水中,配制1%(w/v)的PVA溶液。100 mg of PLGA was weighed and dissolved in 1 mL of dichloromethane to prepare a 10% (w/v) solution of PLGA in dichloromethane. Weigh 13.12mg α-cyclodextrin and dissolve it in 1mL water to prepare 13.12mg/mL α-cyclodextrin solution; weigh 145mg PEG-2000 and dissolve it in 1mL water to prepare 145mg/mL PEG solution. Dissolve 2g of PVA in 200mL of water to prepare a 1% (w/v) PVA solution.
取5mg异硫氰酸荧光素标记的牛血清蛋白(FITC-BSA)溶于50μL 145mg/mL的PEG溶液,再与50μL 13.12mg/mL的α-环糊精溶液混合均匀,加入到1mL 10%(w/v)的PLGA的二氯甲烷溶液中,以15W功率超声20s,形成水/油乳化液;将上述水/油乳化液加入到10mL1%(w/v)的PVA溶液中,超声得到水/油/水乳化液。将此乳化液在室温下缓慢搅拌3h,水洗3次,冷冻干燥,即得到多孔聚合物微球。Dissolve 5 mg of fluorescein isothiocyanate-labeled bovine serum albumin (FITC-BSA) in 50 μL of 145 mg/mL PEG solution, mix with 50 μL of 13.12 mg/mL α-cyclodextrin solution, and add to 1 mL of 10% (w/v) in the dichloromethane solution of PLGA, ultrasonic 20s with 15W power, form water/oil emulsion; Add above-mentioned water/oil emulsion in the PVA solution of 10mL1% (w/v), obtain by ultrasonic Water/oil/water emulsion. The emulsion was slowly stirred at room temperature for 3 hours, washed with water three times, and freeze-dried to obtain porous polymer microspheres.
取10mg微球分散在5mL pH=7.4的磷酸盐缓冲液(PBS)中,在第0,1,3……30天,取出2mL,离心,测上清液的荧光强度。从图5的测试结果表明,在第25天时,微球释放了FITC-BSA总量的90%。这说明此法制备的闭孔结构的多孔微球具有长效释放能力。Take 10 mg of microspheres and disperse them in 5 mL of phosphate buffered saline (PBS) with pH=7.4. On days 0, 1, 3...30, take out 2 mL, centrifuge, and measure the fluorescence intensity of the supernatant. The test results from Fig. 5 show that at day 25, the microspheres released 90% of the total amount of FITC-BSA. This shows that the porous microspheres with closed-cell structure prepared by this method have long-term release ability.
实施例12开孔结构的多孔微球的长效释放能力测试:The long-term release ability test of the porous microsphere of embodiment 12 open-pore structure:
称取100mg的PLGA溶于1mL二氯甲烷中,配制10%(w/v)的PLGA的二氯甲烷溶液。称取13.12mgα-环糊精溶于1mL水中,配制成13.12mg/mL的α-环糊精溶液;称取145mg PEG-2000溶于1mL水中,配制145mg/mL的PEG溶液。取2g PVA溶于200mL水中,配制1%(w/v)的PVA溶液。100 mg of PLGA was weighed and dissolved in 1 mL of dichloromethane to prepare a 10% (w/v) solution of PLGA in dichloromethane. Weigh 13.12mg α-cyclodextrin and dissolve it in 1mL water to prepare 13.12mg/mL α-cyclodextrin solution; weigh 145mg PEG-2000 and dissolve it in 1mL water to prepare 145mg/mL PEG solution. Dissolve 2g of PVA in 200mL of water to prepare a 1% (w/v) PVA solution.
取50μL 13.12mg/mL的α-环糊精溶液与50μL 145mg/mL的PEG溶液混合均匀,加入到1mL 10%(w/v)的PLGA的二氯甲烷溶液中,以15W功率超声20s,形成水/油乳化液;将上述水/油乳化液加入到10mL 1%(w/v)的PVA溶液中,超声得到水/油/水乳化液。将此乳化液在室温下200-600r/min下缓慢搅拌24h,水洗3次,分散在5mL水中,加入5mg FITC-BSA(异硫氰酸标记的牛血清蛋白),搅拌24h,离心,重新分散在水中,冷冻干燥,得到开孔结构的微球。取10mg开孔结构的微球分散在5mL pH=7.4的PBS缓冲液中,在第0,1,3,5,7天取出2mL离心,并将上清液测荧光,测试后再将上清液与离心后的固体超声后再放入到PBS缓冲液中。由图5的分析结果可知,在第5天时,微球释放量达到了总量的90%。Take 50 μL of 13.12 mg/mL α-cyclodextrin solution and 50 μL of 145 mg/mL PEG solution, mix evenly, add to 1 mL of 10% (w/v) PLGA in dichloromethane solution, and sonicate at 15W for 20s to form Water/oil emulsion: the above water/oil emulsion was added to 10 mL of 1% (w/v) PVA solution, and the water/oil/water emulsion was obtained by ultrasonication. Stir the emulsion slowly at room temperature at 200-600r/min for 24h, wash it with water three times, disperse it in 5mL water, add 5mg FITC-BSA (bovine serum albumin labeled with isothiocyanate), stir for 24h, centrifuge, and redisperse Freeze-dried in water to obtain microspheres with open-pore structure. Disperse 10 mg of microspheres with an open pore structure in 5 mL of PBS buffer at pH = 7.4, take out 2 mL of microspheres on days 0, 1, 3, 5, and 7, and measure the fluorescence of the supernatant. After the test, the supernatant The solution and the centrifuged solid were sonicated and then put into PBS buffer. From the analysis results in Fig. 5, it can be known that on the 5th day, the released amount of microspheres reached 90% of the total amount.
由此可见,本方法制备的两种不同孔结构的多孔微球具有不同的释放性能。It can be seen that the porous microspheres with two different pore structures prepared by this method have different release properties.
实施例13Example 13
取6mg海藻酸钠溶解在300μL去离子水中,分别取实施例2和实施例4中制备的微球各10mg,将其分散在海藻酸钠溶液中。将上述分散液均匀铺展在载玻片上,再将300μL0.5mol/L的氯化钙溶液滴加于其上,用另一块载玻片轻轻压制30min,得到凝胶贴片1。将此整块的凝胶贴片裁割为直径约50dm的圆形贴片,备用。6 mg of sodium alginate was dissolved in 300 μL of deionized water, and 10 mg of the microspheres prepared in Example 2 and Example 4 were respectively taken and dispersed in the sodium alginate solution. The above dispersion was evenly spread on a glass slide, and then 300 μL of 0.5 mol/L calcium chloride solution was added dropwise on it, and another glass slide was used to gently press for 30 minutes to obtain a gel patch 1. Cut the entire piece of gel patch into a circular patch with a diameter of about 50dm for later use.
实施例14Example 14
将实施例2中制备的微球分散在5mL去离子水中,加入10mg白介素(IL-4),在冰浴下搅拌24h后冻干燥,得到装载有白介素的微球,备用。The microspheres prepared in Example 2 were dispersed in 5 mL of deionized water, 10 mg of interleukin (IL-4) was added, stirred in an ice bath for 24 h, and then freeze-dried to obtain microspheres loaded with interleukin for future use.
取6mg海藻酸钠溶解在300μL去离子水中,取20mg上述装载有白介素的微球分散在此海藻酸钠溶液中。将此分散液均匀铺展在载玻片上,再将300μL 0.5mol/L的氯化钙溶液滴加于其上,用另一块载玻片轻轻压制30min,得到凝胶贴片2。将此整块的凝胶贴片裁割为直径约50dm的圆形贴片,备用。6 mg of sodium alginate was dissolved in 300 μL of deionized water, and 20 mg of the above-mentioned interleukin-loaded microspheres were dispersed in the sodium alginate solution. The dispersion was evenly spread on a glass slide, and then 300 μL of 0.5 mol/L calcium chloride solution was added dropwise on it, and another glass slide was gently pressed for 30 minutes to obtain gel patch 2. Cut the entire piece of gel patch into a circular patch with a diameter of about 50dm for later use.
实施例15Example 15
称取100mg的PLGA溶于1mL二氯甲烷中,配制10%(w/v)的PLGA的二氯甲烷溶液。称取13.12mgα-环糊精溶于1mL水中,配制13.12mg/mL的α-环糊精溶液;称取145mg PEG-2000溶于1mL水中,配制145mg/mL的PEG溶液。取2g PVA溶于200mL水中,配制1%(w/v)的PVA溶液。100 mg of PLGA was weighed and dissolved in 1 mL of dichloromethane to prepare a 10% (w/v) solution of PLGA in dichloromethane. Weigh 13.12mg α-cyclodextrin and dissolve it in 1mL water to prepare 13.12mg/mL α-cyclodextrin solution; weigh 145mg PEG-2000 and dissolve it in 1mL water to prepare 145mg/mL PEG solution. Dissolve 2g of PVA in 200mL of water to prepare a 1% (w/v) PVA solution.
取10mg褪黑素溶于50μL 145mg/mL的PEG溶液,再与50μL 13.12mg/mL的α-环糊精溶液混合均匀,加入到1mL 10%(w/v)的PLGA的二氯甲烷溶液中,以15W功率超声20s,形成水/油乳化液;将上述水/油乳化液加入到10mL 1%(w/v)的PVA溶液中,超声得到水/油/水乳化液。将此乳化液在室温下200-600r/min下缓慢搅拌3h,水洗3次,冷冻干燥,即得到含褪黑素的内部多孔的聚合物微球。Dissolve 10 mg of melatonin in 50 μL of 145 mg/mL PEG solution, mix well with 50 μL of 13.12 mg/mL α-cyclodextrin solution, and add to 1 mL of 10% (w/v) PLGA in dichloromethane , ultrasonication with 15W power for 20s to form a water/oil emulsion; the above water/oil emulsion was added to 10mL of 1% (w/v) PVA solution, and ultrasonically obtained a water/oil/water emulsion. The emulsion was slowly stirred at room temperature at 200-600 r/min for 3 hours, washed with water three times, and freeze-dried to obtain internally porous polymer microspheres containing melatonin.
取6mg海藻酸钠溶解在300μL去离子水中,取20mg含褪黑素的内部多孔的聚合物微球分散在此海藻酸钠溶液中。将此分散液均匀铺展在载玻片上,再将一定体积0.5mol/L的氯化钙溶液滴加于其上,用另一块载玻片轻轻压制30min,得到凝胶贴片3。将此整块的凝胶贴片裁割为直径约50dm的圆形贴片,备用。6 mg of sodium alginate was dissolved in 300 μL of deionized water, and 20 mg of internally porous polymer microspheres containing melatonin were dispersed in the sodium alginate solution. The dispersion was evenly spread on a glass slide, and a certain volume of 0.5 mol/L calcium chloride solution was added dropwise on it, and another glass slide was used to gently press for 30 minutes to obtain a gel patch 3 . Cut the entire piece of gel patch into a circular patch with a diameter of about 50dm for later use.
实施例16Example 16
取6mg海藻酸钠溶解在300μL去离子水中,分别取实施例14与实施例15中装有白介素和褪黑素的微球各10mg,将其全部分散在海藻酸钠溶液中。将上述分散液均匀铺展在载玻片上,再将一定体积0.5mol/L的氯化钙溶液滴加于其上,用另一块载玻片轻轻压制30min,得到凝胶贴片4。将此整块的凝胶贴片裁割为直径约50dm的圆形贴片,备用。Dissolve 6 mg of sodium alginate in 300 μL of deionized water, take 10 mg of microspheres containing interleukin and melatonin in Example 14 and Example 15, and disperse them all in the sodium alginate solution. Spread the dispersion above evenly on a glass slide, then drop a certain volume of 0.5 mol/L calcium chloride solution on it, and gently press it with another glass slide for 30 minutes to obtain the gel patch 4 . Cut the entire piece of gel patch into a circular patch with a diameter of about 50dm for later use.
实施例17Example 17
分别取实施例13、14、15、16中的凝胶贴片1、凝胶贴片2、凝胶贴片3和凝胶贴片4处理小鼠伤口,拍照记录小鼠的伤口愈合情况,并计算其愈合率。结果如图6和图7所示。图4结果表明,用实施例16的凝胶贴片处理小鼠伤口后,小鼠伤口愈合情况最好,即在IL-4与褪黑素的共同作用下,小鼠伤口愈合效果最好。在处理小鼠伤口7天后,检测其M2阳性巨噬细胞数量,检测结果如图8和图9所示。结果表明,IL-4对促进巨噬细胞向M2阳性巨噬细胞分化起主要作用。并在7天后检测血管内皮生长因子(VEGF)与血管紧张素Ⅱ(AngⅡ)含量,检测结果如图10和图11所示。结果表明褪黑素对于促进血管形成起到主要作用。Take the gel patch 1, gel patch 2, gel patch 3 and gel patch 4 in Examples 13, 14, 15, and 16 respectively to treat mouse wounds, take pictures and record the wound healing of the mice, And calculate its healing rate. The results are shown in Figure 6 and Figure 7. The results in Fig. 4 show that after treating the mouse wound with the gel patch of Example 16, the wound healing of the mouse is the best, that is, under the joint action of IL-4 and melatonin, the wound healing effect of the mouse is the best. After treating the mouse wound for 7 days, the number of M2-positive macrophages was detected, and the detection results are shown in Fig. 8 and Fig. 9 . The results showed that IL-4 played a major role in promoting the differentiation of macrophages into M2-positive macrophages. After 7 days, the contents of vascular endothelial growth factor (VEGF) and angiotensin II (Ang II) were detected, and the detection results are shown in Fig. 10 and Fig. 11 . The results suggest that melatonin plays a major role in promoting angiogenesis.
本发明制得的不同孔结构的多孔聚合物微球可用于装载不同种类的生物分子。实施例16将这两种微球结合起来作为生物分子载体,既能对其起到保护作用,又可以选择性地释放出组织和器官再生不同阶段所需要的生物分子。The porous polymer microspheres with different pore structures prepared by the present invention can be used to load different types of biomolecules. In Example 16, these two kinds of microspheres were combined as biomolecule carriers, which can not only protect them, but also selectively release biomolecules required in different stages of tissue and organ regeneration.
实施例18Example 18
环糊精溶液是将环糊精加入到水中制得,环糊精溶液的浓度为3mg/mL;其中,环糊精为γ-环糊精;The cyclodextrin solution is prepared by adding cyclodextrin to water, and the concentration of the cyclodextrin solution is 3mg/mL; wherein, the cyclodextrin is γ-cyclodextrin;
聚乙二醇溶液是将聚乙二醇加入到水中制得,聚乙二醇溶液的浓度为50mg/mL;聚乙二醇的摩尔质量为2000g;Polyethylene glycol solution is prepared by adding polyethylene glycol into water, the concentration of polyethylene glycol solution is 50mg/mL; the molar mass of polyethylene glycol is 2000g;
PLGA的二氯甲烷溶液是将PLGA加入到二氯甲烷中制得,PLGA的二氯甲烷溶液的浓度为50mg/mL。The dichloromethane solution of PLGA is prepared by adding PLGA into dichloromethane, and the concentration of the PLGA dichloromethane solution is 50 mg/mL.
PVA溶液是将PVA加入到水中制得,PVA溶液的质量浓度为5mg/mL;PVA的摩尔质量为120000g。The PVA solution is prepared by adding PVA to water, the mass concentration of the PVA solution is 5mg/mL; the molar mass of the PVA is 120000g.
将环糊精溶液与聚乙二醇溶液混合后,加入到PLGA的二氯甲烷溶液中,超声得到水/油乳化液,将水/油乳化液加入到PVA溶液中,10W下超声60s得到水/油/水乳化液,将水/油/水乳化液在室温下搅拌3h后,水洗,冷冻干燥得到多孔聚合物微球;其中,环糊精、聚乙二醇、PLGA与PVA的质量比为0.656:7.25:100:100。After mixing the cyclodextrin solution and the polyethylene glycol solution, add it to the dichloromethane solution of PLGA, ultrasonically obtain the water/oil emulsion, add the water/oil emulsion into the PVA solution, and ultrasonicate for 60 seconds at 10W to obtain water /oil/water emulsion, the water/oil/water emulsion was stirred at room temperature for 3h, washed with water, and freeze-dried to obtain porous polymer microspheres; wherein, the mass ratio of cyclodextrin, polyethylene glycol, PLGA to PVA It is 0.656:7.25:100:100.
实施例19Example 19
环糊精溶液是将环糊精加入到水中制得,环糊精溶液的浓度为15mg/mL;其中,环糊精为β-环糊精;The cyclodextrin solution is prepared by adding cyclodextrin to water, and the concentration of the cyclodextrin solution is 15 mg/mL; wherein, the cyclodextrin is β-cyclodextrin;
聚乙二醇溶液是将聚乙二醇加入到水中制得,聚乙二醇溶液的浓度为150mg/mL;聚乙二醇的摩尔质量为10000g;Polyethylene glycol solution is prepared by adding polyethylene glycol into water, the concentration of polyethylene glycol solution is 150mg/mL; the molar mass of polyethylene glycol is 10000g;
PLGA的二氯甲烷溶液是将PLGA加入到二氯甲烷中制得,PLGA的二氯甲烷溶液的浓度为200mg/mL。The dichloromethane solution of PLGA is prepared by adding PLGA into dichloromethane, and the concentration of the PLGA dichloromethane solution is 200 mg/mL.
PVA溶液是将PVA加入到水中制得,PVA溶液的质量浓度为20mg/mL;PVA的摩尔质量为75000g。The PVA solution is prepared by adding PVA to water, the mass concentration of the PVA solution is 20mg/mL; the molar mass of the PVA is 75000g.
将环糊精溶液与聚乙二醇溶液混合后,加入到PLGA的二氯甲烷溶液中,超声得到水/油乳化液,将水/油乳化液加入到PVA溶液中,100W下超声10s得到水/油/水乳化液,将水/油/水乳化液在室温下搅拌24h后,水洗,冷冻干燥得到多孔聚合物微球;其中,环糊精、聚乙二醇、PLGA与PVA的质量比为0.656:7.25:100:100。After mixing the cyclodextrin solution and the polyethylene glycol solution, add it to the dichloromethane solution of PLGA, ultrasonically obtain a water/oil emulsion, add the water/oil emulsion into the PVA solution, and ultrasonically obtain water at 100W for 10s /oil/water emulsion, the water/oil/water emulsion was stirred at room temperature for 24h, washed with water, and freeze-dried to obtain porous polymer microspheres; wherein, the mass ratio of cyclodextrin, polyethylene glycol, PLGA to PVA It is 0.656:7.25:100:100.
实施例20Example 20
环糊精溶液是将环糊精加入到水中制得,环糊精溶液的浓度为8mg/mL;其中,环糊精为γ-环糊精;The cyclodextrin solution is prepared by adding cyclodextrin to water, and the concentration of the cyclodextrin solution is 8 mg/mL; wherein, the cyclodextrin is γ-cyclodextrin;
聚乙二醇溶液是将聚乙二醇加入到水中制得,聚乙二醇溶液的浓度为100mg/mL;聚乙二醇的摩尔质量为50000g;Polyethylene glycol solution is prepared by adding polyethylene glycol into water, the concentration of polyethylene glycol solution is 100mg/mL; the molar mass of polyethylene glycol is 50000g;
PLGA的二氯甲烷溶液是将PLGA加入到二氯甲烷中制得,PLGA的二氯甲烷溶液的浓度为300mg/mL。The dichloromethane solution of PLGA is prepared by adding PLGA into dichloromethane, and the concentration of the PLGA dichloromethane solution is 300 mg/mL.
PVA溶液是将PVA加入到水中制得,PVA溶液的质量浓度为15mg/mL;PVA的摩尔质量为15000g。The PVA solution is prepared by adding PVA to water, the mass concentration of the PVA solution is 15mg/mL; the molar mass of the PVA is 15000g.
将环糊精溶液与聚乙二醇溶液混合后,加入到PLGA的二氯甲烷溶液中,超声得到水/油乳化液,将水/油乳化液加入到PVA溶液中,50W下超声30s得到水/油/水乳化液,将水/油/水乳化液在室温下搅拌8h后,水洗,冷冻干燥得到多孔聚合物微球;其中,环糊精、聚乙二醇、PLGA与PVA的质量比为0.656:7.25:100:100。After mixing the cyclodextrin solution and the polyethylene glycol solution, add it to the dichloromethane solution of PLGA, ultrasonically obtain the water/oil emulsion, add the water/oil emulsion into the PVA solution, and ultrasonicate for 30 seconds at 50W to obtain water /oil/water emulsion, the water/oil/water emulsion was stirred at room temperature for 8h, washed with water, and freeze-dried to obtain porous polymer microspheres; wherein, the mass ratio of cyclodextrin, polyethylene glycol, PLGA to PVA It is 0.656:7.25:100:100.
本发明中闭孔结构的多孔聚合物微球与开孔结构的多孔聚合物微球的总和、装载有白介素的微球以及含褪黑素的内部多孔的聚合物微球与海藻酸钠溶液的比可以为10mg~40mg:500μL,本发明中仅以10mg:500μL为例进行说明。本发明中海藻酸钠浓度可以为10~30mg/mL,本发明中仅以20mg/mL为例进行说明。本发明中氯化钙浓度可以为0.2~0.8mol/L,本发明中仅以0.5mol/L为例进行说明。In the present invention, the sum of the porous polymer microspheres of the closed-cell structure and the porous polymer microspheres of the open-pore structure, the microspheres loaded with interleukin and the internal porous polymer microspheres containing melatonin and the sodium alginate solution The ratio can be 10 mg-40 mg:500 μL, and the present invention only uses 10 mg:500 μL as an example for illustration. The concentration of sodium alginate in the present invention can be 10-30 mg/mL, and the present invention only takes 20 mg/mL as an example for illustration. The concentration of calcium chloride in the present invention can be 0.2-0.8 mol/L, and only 0.5 mol/L is taken as an example in the present invention for illustration.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710916206.2A CN107698795B (en) | 2017-09-30 | 2017-09-30 | Preparation method and application of porous polymer microspheres with controllable structures |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710916206.2A CN107698795B (en) | 2017-09-30 | 2017-09-30 | Preparation method and application of porous polymer microspheres with controllable structures |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107698795A true CN107698795A (en) | 2018-02-16 |
CN107698795B CN107698795B (en) | 2020-10-27 |
Family
ID=61183936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710916206.2A Active CN107698795B (en) | 2017-09-30 | 2017-09-30 | Preparation method and application of porous polymer microspheres with controllable structures |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107698795B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110934850A (en) * | 2019-11-18 | 2020-03-31 | 中国人民解放军军事科学院军事医学研究院 | Composite nano-drug particles with acute antioxidant and hypoxia response functions and preparation method |
CN113527752A (en) * | 2021-07-23 | 2021-10-22 | 中国科学院苏州纳米技术与纳米仿生研究所 | Closed-cell aerogel microspheres, and preparation method and application thereof |
CN113913096A (en) * | 2021-09-24 | 2022-01-11 | 四川汇园宝新材料科技有限公司 | Antiviral coating and preparation method thereof |
CN114345252A (en) * | 2021-12-28 | 2022-04-15 | 华熙生物科技股份有限公司 | Polymer microsphere and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1660412A (en) * | 2004-12-27 | 2005-08-31 | 中山大学 | A kind of preparation method of interferon polylactic acid-glycolic acid copolymer PLGA microsphere |
CN101249077A (en) * | 2008-04-14 | 2008-08-27 | 西南交通大学 | A kind of preparation method and application of degradable polymer porous microsphere |
CN104689323A (en) * | 2015-01-23 | 2015-06-10 | 上海大学 | Oil-soluble drug microsphere with slow release function and preparation method thereof |
US20160199314A1 (en) * | 2013-08-21 | 2016-07-14 | Swansea University | Topical drug patch including microspheres |
-
2017
- 2017-09-30 CN CN201710916206.2A patent/CN107698795B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1660412A (en) * | 2004-12-27 | 2005-08-31 | 中山大学 | A kind of preparation method of interferon polylactic acid-glycolic acid copolymer PLGA microsphere |
CN101249077A (en) * | 2008-04-14 | 2008-08-27 | 西南交通大学 | A kind of preparation method and application of degradable polymer porous microsphere |
US20160199314A1 (en) * | 2013-08-21 | 2016-07-14 | Swansea University | Topical drug patch including microspheres |
CN104689323A (en) * | 2015-01-23 | 2015-06-10 | 上海大学 | Oil-soluble drug microsphere with slow release function and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
MASSIMO CECCATO ET AL.: "α-Cyclodextrin/Polyethylene Glycol Polyrotaxane: A Study of the Threading Process", 《LANGMUIR》 * |
叶霖 等: "《环糊精自组装 ——一种新型超分子材料的制备与应用》", 30 November 2013, 北京理工大学出版社 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110934850A (en) * | 2019-11-18 | 2020-03-31 | 中国人民解放军军事科学院军事医学研究院 | Composite nano-drug particles with acute antioxidant and hypoxia response functions and preparation method |
CN113527752A (en) * | 2021-07-23 | 2021-10-22 | 中国科学院苏州纳米技术与纳米仿生研究所 | Closed-cell aerogel microspheres, and preparation method and application thereof |
CN113913096A (en) * | 2021-09-24 | 2022-01-11 | 四川汇园宝新材料科技有限公司 | Antiviral coating and preparation method thereof |
CN114345252A (en) * | 2021-12-28 | 2022-04-15 | 华熙生物科技股份有限公司 | Polymer microsphere and preparation method thereof |
CN114345252B (en) * | 2021-12-28 | 2022-09-02 | 华熙生物科技股份有限公司 | Polymer microsphere and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN107698795B (en) | 2020-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Dynamic covalent constructed self-healing hydrogel for sequential delivery of antibacterial agent and growth factor in wound healing | |
He et al. | Conductive adhesive self-healing nanocomposite hydrogel wound dressing for photothermal therapy of infected full-thickness skin wounds | |
Yuan et al. | Emulsion template method for the fabrication of gelatin-based scaffold with a controllable pore structure | |
Wang et al. | Construction of injectable self-healing macroporous hydrogels via a template-free method for tissue engineering and drug delivery | |
JP7445273B2 (en) | Fiber-hydrogel composite surgical mesh for tissue repair | |
Sun et al. | Engineering dextran-based scaffolds for drug delivery and tissue repair | |
Zhu et al. | Responsive hydrogels based on triggered click reactions for liver cancer | |
US8388948B2 (en) | Cytocompatible alginate gels | |
He et al. | Nanocellulose-based hydrogels as versatile drug delivery vehicles: A review | |
Motasadizadeh et al. | Dual drug delivery system of teicoplanin and phenamil based on pH-sensitive silk fibroin/sodium alginate hydrogel scaffold for treating chronic bone infection | |
Sun et al. | Mussel-inspired polysaccharide-based sponges for hemostasis and bacteria infected wound healing | |
CN107698795B (en) | Preparation method and application of porous polymer microspheres with controllable structures | |
CN107708675A (en) | The composition and kit of pseudoplastic behavior microgel matrix | |
WO2020147754A1 (en) | Cubic cyclodextrin framework-rgd composition and preparation method therefor | |
Jin et al. | Nanofibers and hydrogel hybrid system with synergistic effect of anti-inflammatory and vascularization for wound healing | |
JP2021522938A (en) | Nanofiber-hydrogel complex for cell and tissue delivery | |
TW200831056A (en) | Hydrogel wound dressing and biomaterials formed in situ and their uses | |
Li et al. | Self-healing hydrogels for bone defect repair | |
CN105233325A (en) | Thermosensitive dual-administration nanocomposite hydrogel as well as preparation method and application thereof | |
Chen et al. | An injectable, wound-adapting, self-healing hydrogel for fibroblast growth factor 2 delivery system in tissue repair applications | |
CN110743038A (en) | Double-network structure composite hydrogel and preparation method and application thereof | |
Hou et al. | Oppositely charged polyurethane microspheres with tunable zeta potentials as an injectable dual-loaded system for bone repair | |
CN101011600A (en) | Decalcification bone supporting stand with composite microsphere of stress release control function and its preparing process | |
Gu et al. | Thermosensitive nanocomposite hydrogel composed of PVPylated poly (D, L-alanine) and laponite as an injectable and bioactive biomaterial | |
Del Prado-Audelo et al. | Current progress of self-healing polymers for medical applications in tissue engineering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201231 Address after: 221000 Shimao Square Inner Commercial Street 2, Office 1, Office 2, Building 1-910, Yunlong District, Xuzhou City, Jiangsu Province Patentee after: Jiangsu Shifeng Enterprise Management Consulting Co.,Ltd. Address before: Beilin District Xianning West Road 710049, Shaanxi city of Xi'an province No. 28 Patentee before: XI'AN JIAOTONG University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210609 Address after: No. 11012, 10th floor, unit 1, building 1, Wangjing international building, Fengcheng 6th Road, Xi'an Economic and Technological Development Zone, Xi'an City, Shaanxi Province, 710000 Patentee after: XI'AN KAIERWEN PETROCHEMICAL AUXILIARIES MANUFACTURING Co.,Ltd. Address before: 221000 Shimao Square Inner Commercial Street 2, Office 1, Office 2, Building 1-910, Yunlong District, Xuzhou City, Jiangsu Province Patentee before: Jiangsu Shifeng Enterprise Management Consulting Co.,Ltd. |